Members of HealthSpring to receive costs of administering the H1N1 flu vaccination

NewsGuard 100/100 Score

HealthSpring will cover the costs of administering the H1N1 (swine) flu vaccination to its members as the vaccine becomes available.

“We are fully supporting all government efforts for managing the H1N1 virus,” HealthSpring Chief Medical Officer Dirk Wales said. “That includes covering the administrative costs for the vaccine for providers who treat HealthSpring members.”

The federal government has said it will provide the H1N1 vaccine at no cost to at-risk groups and is asking insurers to cover the administration costs.

The vaccine is being prioritized first for pregnant women, caregivers of children under six months, healthcare and emergency medical services personnel, children and young adults six months to 24 years, and persons 25 to 64 who have health conditions that might increase their risk for flu complications. Other individuals will then receive the H1N1 vaccine as it becomes available.

HealthSpring members with questions about swine flu or the vaccine should talk to their doctors. For questions about HealthSpring benefits or coverage, visit the HealthSpring web site at www.healthspring.com.

Source:

HealthSpring

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Researchers develop promising recombinant flu vaccine using nanoliposome technology